Status:
COMPLETED
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Lead Sponsor:
Sohag University
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
Brief Summary
Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct ...
Detailed Description
Pancreatic duct adenocarcinoma (PDAC) is a deadly neoplasm that showed current increase in its occurrence. There are many challenges in PDAC; the tumor is frequently associated with perineural invasio...
Eligibility Criteria
Inclusion
- Cases of PDAC who underwent radical operations.
- Tissue blocks with sufficient material.
- Cases with available clinical data.
Exclusion
- Cases of pancreatic carcinoma other than PDAC.
- Patients who received preoperative chemotherapy or radiotherapy.
- Patients with PDAC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
- Cases with insufficient/destructed material.
- Patients with inadequate clinical data.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT06055647
Start Date
January 1 2017
End Date
December 31 2020
Last Update
September 28 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.